PTK2 and central nervous system cancer: Once released, soluble NLGN3 (sNLGN3) diffuses to glioma cells and binds surface receptors, inducing the FAK-PI3K-mTOR signaling pathway that results in glioma cell proliferation [32,84,85,86].